Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Other Non-Current Liabilities (2022 - 2025)

Senti Biosciences has reported Other Non-Current Liabilities over the past 4 years, most recently at $8.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $8.1 million for Q4 2025, up 60.41% from a year ago — trailing twelve months through Dec 2025 was $8.1 million (up 60.41% YoY), and the annual figure for FY2025 was $8.1 million, up 60.41%.
  • Other Non-Current Liabilities for Q4 2025 was $8.1 million at Senti Biosciences, up from $7.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for SNTI hit a ceiling of $8.1 million in Q4 2025 and a floor of $20000.0 in Q2 2023.
  • Median Other Non-Current Liabilities over the past 4 years was $909000.0 (2022), compared with a mean of $3.2 million.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 97.53% in 2023 and later surged 32695.0% in 2025.
  • Senti Biosciences' Other Non-Current Liabilities stood at $227000.0 in 2022, then soared by 1670.93% to $4.0 million in 2023, then grew by 25.6% to $5.0 million in 2024, then surged by 60.41% to $8.1 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $8.1 million (Q4 2025), $7.6 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.